These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
214 related articles for article (PubMed ID: 19649333)
1. Bendamustine hydrochloride - a renaissance of alkylating strategies in anticancer medicine. Eichbaum M; Bischofs E; Nehls K; Schneeweiss A; Sohn C Drugs Today (Barc); 2009 Jun; 45(6):431-44. PubMed ID: 19649333 [TBL] [Abstract][Full Text] [Related]
2. Bendamustine as a model for the activity of alkylating agents. Apostolopoulos C; Castellano L; Stebbing J; Giamas G Future Oncol; 2008 Jun; 4(3):323-32. PubMed ID: 18518757 [TBL] [Abstract][Full Text] [Related]
3. Phase I studies with bendamustine: an update. Schrijvers D; Vermorken JB Semin Oncol; 2002 Aug; 29(4 Suppl 13):15-8. PubMed ID: 12170427 [TBL] [Abstract][Full Text] [Related]
5. Bendamustine: rescue of an effective antineoplastic agent from the mid-twentieth century. Leoni LM Semin Hematol; 2011 Apr; 48 Suppl 1():S4-11. PubMed ID: 21530771 [TBL] [Abstract][Full Text] [Related]
6. Bendamustine for the treatment of indolent non-Hodgkin's lymphoma and chronic lymphocytic leukemia. Elefante A; Czuczman MS Am J Health Syst Pharm; 2010 May; 67(9):713-23. PubMed ID: 20410545 [TBL] [Abstract][Full Text] [Related]
8. Bendamustine: mechanism of action and clinical data. Cheson BD; Leoni L Clin Adv Hematol Oncol; 2011 Aug; 9(8 Suppl 19):1-11. PubMed ID: 22362008 [TBL] [Abstract][Full Text] [Related]
9. Bendamustine: a new therapeutic option for hematologic malignancies. Cheson BD Clin Adv Hematol Oncol; 2008 Sep; 6(9):631-3. PubMed ID: 18827785 [No Abstract] [Full Text] [Related]
10. Bendamustine: rebirth of an old drug. Cheson BD; Rummel MJ J Clin Oncol; 2009 Mar; 27(9):1492-501. PubMed ID: 19224851 [TBL] [Abstract][Full Text] [Related]
11. Metabolism and mechanisms of action of bendamustine: rationales for combination therapies. Gandhi V Semin Oncol; 2002 Aug; 29(4 Suppl 13):4-11. PubMed ID: 12170425 [TBL] [Abstract][Full Text] [Related]
12. Bendamustine in the treatment of hematologic malignancies. Introduction. Diehl V; Cheson BD Semin Oncol; 2002 Aug; 29(4 Suppl 13):1-3. PubMed ID: 12170424 [No Abstract] [Full Text] [Related]
13. Bendamustine in non-Hodgkin lymphoma: the double-agent that came from the Cold War. Forero-Torres A; Saleh MN Clin Lymphoma Myeloma; 2007 Dec; 8 Suppl 1():S13-7. PubMed ID: 18282361 [TBL] [Abstract][Full Text] [Related]
14. Bendamustine for the treatment of chronic lymphocytic leukemia and rituximab-refractory, indolent B-cell non-Hodgkin lymphoma. Dennie TW; Kolesar JM Clin Ther; 2009; 31 Pt 2():2290-311. PubMed ID: 20110042 [TBL] [Abstract][Full Text] [Related]
15. A phase I study of bendamustine hydrochloride administered once every 3 weeks in patients with solid tumors. Rasschaert M; Schrijvers D; Van den Brande J; Dyck J; Bosmans J; Merkle K; Vermorken JB Anticancer Drugs; 2007 Jun; 18(5):587-95. PubMed ID: 17414628 [TBL] [Abstract][Full Text] [Related]
16. Bendamustine monotherapy in advanced and refractory chronic lymphocytic leukemia. Kath R; Blumenstengel K; Fricke HJ; Höffken K J Cancer Res Clin Oncol; 2001 Jan; 127(1):48-54. PubMed ID: 11206271 [TBL] [Abstract][Full Text] [Related]